Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Biocell Natural Killer Mixture + R-CHOP** is a combination therapy that consists of a preparation referred to as "Biocell Natural Killer Mixture" (which is likely a supplement, preparation, or product designed to enhance or provide natural killer (NK) cell activity) and the established R-CHOP chemotherapy regimen. R-CHOP is widely used as first-line treatment for various B-cell non-Hodgkin lymphomas and is composed of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. The intended mechanism behind combining an NK cell-activator with R-CHOP is to potentially improve antitumor efficacy by synergistically enhancing immune-mediated cytotoxicity alongside cytotoxic chemotherapy and monoclonal antibody therapy[2][5][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biocell Natural Killer Mixture + R-CHOP.